Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-01-28FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Lexapro (escitalopram) by Allergan, Inc. The action updates the product labeling per the approve…
-
FDA approval · 2016-01-26FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2016-01-22FDA Approved: ESCITALOPRAM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for escitalopram from Rising Pharma Holdings, Inc.
-
FDA approval · 2016-01-20FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approves a supplemental application for venlafaxine hydrochloride submitted by Zydus Pharmaceuticals USA Inc., resulting in regulatory a…
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting [NA]
This entry summarizes the completion of an open trial evaluating internet-delivered treatment for children with anxiety disorders in a rural…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-01-15Clinical Trial Update: Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder [Phase 2]
This Phase 2 study reports pharmacokinetics and tolerability of vortioxetine in children and adolescents with depressive or anxiety disorder…
-
CLINICAL_TRIALS trial_result · 2016-01-12Clinical Trial Update: Calmer Life: Testing the Effectiveness of a Treatment for Anxiety [NA]
This clinical trial update notes the completion of a study at Baylor College of Medicine evaluating a treatment for generalized anxiety diso…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Sleep, Mood, and Behavior Study [NA]
A completed clinical trial update from the University of Pittsburgh reports on sleep, mood, and behavior in children with anxiety disorders,…
-
CLINICAL_TRIALS trial_result · 2016-01-07Clinical Trial Update: Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder [NA]
A completed clinical trial evaluated transcranial magnetic stimulation for generalized anxiety disorder. Results were posted in 2016.
-
FDA approval · 2016-01-05FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Escitalopram Oxalate from Rising Pharma Holdings, Inc., confirming continued approval of thi…
-
CLINICAL_TRIALS trial_result · 2015-12-29Clinical Trial Update: Motivational Interviewing and Cognitive Behavioural Therapy for Generalized Anxiety Disorder [NA]
This clinical trial update summarizes a completed study evaluating Motivational Interviewing and Cognitive Behavioral Therapy for Generalize…
-
CLINICAL_TRIALS trial_result · 2015-12-23Clinical Trial Update: Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels [Phase 1]
A Phase 1 clinical trial evaluated whether gastric bypass surgery affects blood levels of the antidepressant venlafaxine ER.
-
FDA approval · 2015-12-22FDA Approved: DULOXETINE DELAYED-RELEASE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental application for a duloxetine hydrochloride delayed-release product, granting app…
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: rTMS Treatment in Patients With General Anxiety Disorder [NA]
A completed clinical trial evaluating repetitive transcranial magnetic stimulation (rTMS) for generalized anxiety disorder.
-
FDA approval · 2015-12-16FDA Approved: BUSPIRONE HYDROCHLORIDE — Original Application (Radha Pharmaceuticals, Inc.)
FDA approves Radha Pharmaceuticals' original application (ANDA) for buspirone hydrochloride, a generic version of an anxiolytic used to reli…
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. [Phase 4]
A Phase 4 randomized trial evaluating a behavioral/intervention approach for generalized anxiety disorder, using dyadic peer tutoring and ad…
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020) [Phase 2]
A Phase 2 study (0777-020) evaluated MK0777 in outpatients with generalized anxiety disorder. The trial status is completed.
-
FDA approval · 2015-11-12FDA Approved: ESCITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for escitalopram oxalate manufactured by Aurobindo Pharma Limited, updating the existing approval fo…
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026) [Phase 2]
A Phase 2 trial comparing GEM at 1.5 mg twice daily and 4.5 mg twice daily to lorazepam for generalized anxiety disorder has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019) [Phase 2]
Phase 2 trial of the MK0777 Gel Extrusion Module for generalized anxiety disorder has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Treatment of Patients With Anxiety Disorder (0777-022) [Phase 2]
Phase 2 trial for Generalized Anxiety Disorder sponsored by Merck Sharp & Dohme LLC has completed. The update does not include efficacy or s…
-
FDA approval · 2015-10-28FDA Approved: ESCITALOPRAM — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
The FDA approved Jubilant Cadista's supplemental application for escitalopram oxalate, a generic version of escitalopram.
-
FDA approval · 2015-10-28FDA Approved: DULOXETINE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' original ANDA for duloxetine, allowing a generic version to be marketed. The approval covers duloxetin…
-
FDA approval · 2015-10-23FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for escitalopram oral solution from Chartwell RX, LLC, enabling a generic oral formulation. This app…
-
FDA label_change · 2015-10-19FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Escitalopram Oxalate by Exelan Pharmaceuticals, indicating a change to the drug's labeling under…